Investigations of methoxyflurane-induced nephrotoxicity in man have been extensively aided by the use of an animal model. To be of value the animal model must share similar metabolic pathways with man and have the same clinical manifestations of the disease process. The Fischer 344 rat appears to meet these criteria.
Specific anesthetic-induced nephrotoxicity was first reported by Crandell et al. (1) in 13 of 41 patients anesthetized with methoxyflurane (MOF) for abdominal surgery. They noted polyuria with a negative fluid balance, elevation of serum sodium, serum osmolality, and blood urea nitrogen, and fixed urine osmolality close to that of serum. Patients were unable to concentrate urine despite fluid deprivation and vasopressin administration, suggesting that the difficulty was of renal origin and not due to antidiuretic hormone (ADH) deficiency. Impairment lasted from 10 to 20 days in most patients, but in three, abnormalities persisted for longer than one year. In 1971, Mazze et al. (2, 3) reported a controlled, randomized, prospective clinical evaluation of renal function following methoxyflurane anesthesia. Abnormalities were found in all cases; patients exhibited polyuria unresponsive to ADH administration, marked weight loss, delayed return of normal urine concentrating ability, hypernatraemia, serum hyperosmolality, elevated BUN and serum creatinine, increased serum uric acid and a decrease in uric acid clearance. Nephrotoxicity was not permanent in any of these patients.
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Initial Evidence Relating Methoxyflurane
Metabolism to Nephrotoxicity It had been suggested by Taves et al. (4) that a metabolite of methoxyflurane, inorganic fluoride, was related to its nephrotoxicity. They reported increased concentrations of inorganic fluoride in the serum and urine of a patient who had renal dysfunction following methoxyflurane anesthesia. About the same time, Frascino et al (5) noted oxalic acid crystals in renal biopsy specimens and increased urinary oxalic acid excretion in several patients with renal insufficiency following methoxyflurane anesthesia, Mazze et al. (3) subsequently reported increased concentrations of inorganic fluoride in all patients anesthetized with methoxyflurane with the highest levels found in those patients with the greatest impairment of renal function (Fig. 1) . Similarly, patients with clinically evident nephrotoxicity had mean peak oxalic acid excretion significantly greater than patients with laboratory abnormalities only. To explain the increased excretion of inorganic fluoride and oxalic acid following methoxyflurane anesthesia, two complementary metabolic routes for biotransformation of methoxyflurane were proposed (Fig. 2) . Both inorganic fluoride and oxalic acid have nephrotoxic potential with the former the most likely cause of polyuria. 
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Evidence of Methoxyflurane Nephrotoxicity in an Animal Model
A direct cause-effect relationship of methoxyflurane administration and renal dysfunction was still not conclusively established, in part due to the absence of nephrotoxicity in animal experiments (6) . After studying the renal effects of methoxyflurane in five rat strains, Mazze et al. (7) found that Fischer 344 and Buffalo rats metabolized methoxyflurane to a greater extent that the other three strains as evidenced by higher serum and urine inorganic fluoride activity (Fig. 3) . However, only Fischer 344 rats developed functional (Fig. 4) and pathological evidence of a renal lesion (7) . Injection of inorganic fluoride (NaF) produced a much greater degree of renal insufficiency in Fischer 344 rats than in Buffalo rats. It was concluded that there were strain differences among rats in the rate of metabolism of methoxyflurane to inorganic fluoride and in its nephrotoxic effects. A high rate of methoxyflurane metabolism and increased susceptibility to the nephrotoxic effects of inorganic fluoride The Fischer 344 rat is an excellent model for studying methoxyflurane nephrotoxicity in man because (1) both metabolize methoxyflurane to Fand oxalic acid; (2) both develop polyuria after MOF which is proportional to serum inorganic Flevel and is pitressin-resistant; (3) both develop renal function abnormalities (hypernatremia, elevated BUN, polyuria) after methoxyflurane; (4) the degree of nephrotoxicity is proportional to the dose of methoxyflurane.
Etiology of Nephrotoxicity
Studies in both man (2, 11) and animals (7) (8) (9) have shown that the degree of nephrotoxicity following methoxyflurane anesthesia is proportional to the amount of metabolite resulting from biotransformation of the drug. and pathological abnormalities similar to those found after methoxyflurane anesthesia (8) . Injection of oxalic acid did not cause these changes ( Fig. 10 ) (10). In man, acute oxalic acid intoxication results in classical anuric renal failure; chronic elevation of oxalic acid excretion is associated with kidney stone formation (12, 13) . Also there is a known potent inhibitory effect of inorganic fluoride on many enzyme systems, including those thought to be involved in sodium transport (Nat + K+ ATPase) and ADH action (14) . Thus, it is unlikely that oxalic acid is of importance in the production of the acute lesion of methoxyflurane nephrotoxicity. However, it is possible that oxalic acid is a factor in the produc- 
Site and Mechanism of the Acute Renal Lesion
Because polyuria following methoxyflurane anesthesia is ADH-resistant, it was originally postulated (3) that inorganic fluoride caused nephrotoxicity by interfering with the action of ADH in the distal convoluted tubule and collecting duct. However, subsequent animal studies (7) (8) (9) showed that the major pathological lesions were in the proximal convoluted tubule with damage ranging from mitochondrial swelling to necrosis of epithelial cells. Few abnormalities were noted in the distal nephron. In biopsy and autopsy specimens, proximal tubular dilatation, focal necrosis and oxalate crystal deposition also have been described (4, 15, 16 
Evidence of Dose-Related Nephrotoxicity in Man
Although animal studies appeared conclusive, there was still doubt as to the nephrotoxicity of methoxyflurane in man (17) . In part this was due to the fact that in the initial study of surgical patients by Mazze variables which included degree of nephrotoxicity, methoxyflurane dosage and serum inorganic fluoride concentration. Patients anesthetized with a methoxyflurane dose of 2.0 MAC-hr or less* had peak serum inorganic fluoride concentrations below 40 pM; this was not associated with nephrotoxicity (Fig. 11) . The threshold of subclinical toxicity occurred at a dosage of 2.5-3 MAC-hr, corresponding to peak serum inorganic fluoride levels of 50-80 WM. These patients had delayed return to maximum preoperative urine osmolality, unresponsiveness to ADH administration and elevated serum uric acid concentration.
Mild clinical toxicity occurred at a dosage of 5 MAC-hr (serum inorganic fluoride concentration 90-120 M). In addition to the abnormalities noted above, serum hyperosmolality, hypernatremia, polyuria, and low urine osmolality were present. Finally, clinical toxicity occurred in *MAC is the minimum alveolar concentration of anesthetic necessary to prevent movement in response to surgical incision in 50% of patients. MAC hours is determined by multiplying alveolar anesthetic concentration by the duration of administration of anesthetic. all three patients with methoxyflurane dosage greater than 7 MAC-hr (peak serum inorganic fluoride levels 80-175 jAM). Abnormalities in serum and urine variables were even more pronounced than at lower methoxyflurane dosages. In addition, all three patients were resistant to ADH (Fig. 12 ) and had thirst and polyuria which added difficulty to their clinical management. A significant permanent reduction in creatinine clearance was seen only in one patient who received 9 MAC-hr of methoxyflurane and required a course of gentamicin for a postoperative Psuedomonas wound infection. His creatinine clearance was reduced from 107 ml/min prior to gentamicin treatment to 40 ml/min after 4 days of antibiotic therapy (Fig. 13 indicated that the toxicity of methoxyflurane is also increased by concurrent treatment with tetracycline (20) and other potentially nephrotoxic drugs. Finally, a comment about age as a factor in methoxyflurane nephrotoxicity. Nephrotoxicity has not been reported in children. Studies in the Fischer 344 rat animal model suggest this may be due to greater deposition of inorganic fluoride in developing bone, thus lowering serum inorganic fluoride levels (Fig. 14) 
Summary of Factors in the Production of Methoxyflurane Nephrotoxicity
The predominant factors in the production of methoxyflurane nephrotoxicity appear to be mehtoxyflurane dosage and serum inorganic fluoride concentration. It is likely that secondary factors include: (1) a high rate of methoxyflurane metabolism and sensitivity of the kidney to inorganic fluoride toxicity; (2) concurrent treatment with other nephrotoxic drugs; (3) preexisting renal disease; (4) surgery of the urogenital tract, aorta, or renal vasculative; (5) repeat administration, of methoxyflurane due to accumulation of inorganic fluoride and, perhaps, methoxyflurane induction of its own metabolism; and (6) concurrent treatment with enzyme inducing drugs such as phenobarbital.
In summary, investigations of methoxyflurane-induced nephrotoxicity in man have been extensively aided by the use of an animal model. To be of value the animal model must share similar metabolic pathways with man and have the same clinical manifestations of the disease process. The Fischer 344 rat appears to meet these criteria.
